Sanjiv K. Patel
CEO & Chairman of the BoardMr. Sanjiv K. Patel, also known as Sanj, has been the Chief Executive Officer of Kiniksa Pharmaceuticals International, plc (formerly known as Kiniksa Pharmaceuticals, Ltd.) since July 2015. Before founding Kiniksa Pharmaceuticals in 2015, Mr. Patel founded Synageva BioPharma Corp. in June 2008 and served as its President and Chief Executive Officer since June 2008 until June 2015 and also served as its Secretary. He took Synageva public in November 2011, raising more than 1 billion in capital in less than five years and he led the 9.5 billion (including cash) acquisition of Synageva by Alexion Pharmaceuticals in June 2015. He joined Synageva from Genzyme Corporation, where he served as the Head of U.S. Sales, Marketing and Commercial Operations for Genzyme Therapeutics and led the commercial U.S. launch for Myozyme®. He was employed at Genzyme Corporation from 1999 to June 2008, where he held several cross-functional senior leadership roles at Genzyme including Vice President, Clinical Research and Head of the Global Clinical Research Operations Council. He was responsible for clinical operations and development for all cross-business Genzyme products and was instrumental in the path to commercialization for several treatments. Mr. Patel led the Fabrazyme® clinical operations team and development program to FDA approval in April 2003. Prior to Genzyme, he held roles in clinical research and commercial development with increasing levels of responsibility at Burroughs Wellcome, Hoescht Marrion Roussel and Fujisawa Pharmaceuticals. He has 18 years of experience in the pharmaceutical and biotech industries. He has been the Chairman of Kiniksa Pharmaceuticals since July 2015. He was a Director of BioCryst Pharmaceuticals, Inc., from September 29, 2015 until June 20, 2018 and serves as Director of Syros Pharmaceuticals, Inc. since May 2016. Mr. Patel served as a Director at Intercept Pharmaceuticals, Inc. since February 18, 2014 until November 24, 2015. He served as a Director of Synageva BioPharma Corp. from June 2008 to June 22, 2015. Mr. Patel earned his B.Sc. degree with Honors in Pure and Applied Biotechnology from South Bank University, London. He attained his post-graduate management and business degree from Ealing College, London. He completed his Doctorate program in Clinical Pharmacology from King's College and The Wellcome Foundation.
Positions
- Company NameKiniksa Pharmaceuticals International, plcStock CodeKNSAPositionCEO & Chairman of the BoardColleagues
- RMRoss Michael MoatPresident, Executive VP, COO & Principal Operating Officer
- MAMark A. RagosaExecutive VP & CFO
- JFJohn F. PaoliniExecutive VP & Chief Medical Officer
- ETEben TessariConsultant
- KJKimberly Johnston PopovitsIndependent Director
- TRThomas Robert MalleyIndependent Director
- SRStephen Richard BiggarIndependent Director
- RJRobert J. DesnickChairman of Scientific Advisory Board
